BI signs KRAS deal with India's Lupin, as pharma awaits key ...

Boehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting tumours driven by the KRAS mutation.

Boehringer jumps on KRAS cancer drug bandwagon with MD Ander...

Boehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, striking a multi-year oncology research deal with the University of Tex

Boehringer announces IPF deal with Korea's Bridge Biotherape...

Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Boehringer adds to obesity alliance with Denmark’s Gubra

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.

Boehringer looks to enhance COPD care with new registry

Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understan